Search results for "Sorafenib treatment"

showing 2 items of 2 documents

Two large steps forward, one small step back

2018

In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.

SorafenibOncologymedicine.medical_specialtyHepatologybusiness.industryGastroenterologySorafenib treatmentmedicine.diseasedigestive system diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistry030220 oncology & carcinogenesisRegorafenibInternal medicineHepatocellular carcinomaCarcinomamedicineAdvanced disease030211 gastroenterology & hepatologyStage (cooking)Nivolumabbusinessmedicine.drugNature Reviews Gastroenterology & Hepatology
researchProduct

Clinical outcomes with long-term sorafenib treatment: A multicenter, real-life study

2017

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicineSorafenib treatmentIntensive care medicineLife studybusinessTerm (time)Digestive and Liver Disease
researchProduct